TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1968858

Group type: EXPERIMENTAL
Intervention: Scoring system for calculating the dose of vaginal prostaglandin E2 tablets
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard dose of 3 mg vaginal prostaglandin E2 tablets
Number of subjects: 110
Study: 380318

Group type: EXPERIMENTAL
Intervention: Soybean diet (total substitution of animal proteins)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soybean diet with low P/S ratio (0.1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard low lipid diet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soybean diet with added cholesterol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soybean diet without added cholesterol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soybean diet with high P/S fatty acid ratio
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soybean diet for mixed phenotypes (IIB-III)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soybean diet for out-patients
Number of subjects: 60
Study: 6831294

Group type: EXPERIMENTAL
Intervention: 0.375 per cent bupivicaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.375 per cent bupivicaine and one per cent lidocaine hydrochloride
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.375 per cent bupivicaine and one per cent carbonated lidocaine
Number of subjects: 30
Study: 30623420

Group type: EXPERIMENTAL
Intervention: Higher MO3PUFA intake
Number of subjects: 1735
Study: 29947083

Group type: EXPERIMENTAL
Intervention: Burosumab 1 mg/kg subcutaneously every 4 weeks (n = 68)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo (n = 66)
Number of subjects: 134
Study: 27357971

Group type: EXPERIMENTAL
Intervention: 200 mg celecoxib (loading dose the night before surgery then twice daily for 10 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 24813753

Group type: EXPERIMENTAL
Intervention: Immobilization for 15 min after IUI
Number of subjects: 391

Group type: COMPARATOR
Intervention: Immediate mobilization after IUI
Number of subjects: 391
Study: 22815387

Group type: EXPERIMENTAL
Intervention: 24‐h total sleep deprivation (TSD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal sleep (NS)
Number of subjects: 28
Study: 20814217

Group type: EXPERIMENTAL
Intervention: Platelet gel (PG) applied locally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no PG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (PG and control)
Number of subjects: 0
Study: 17413292

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone infusion (2.3 microg/kg/h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 12
Study: 16302557

Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 873
Study: 12151889

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgical treatment (Hohmann operation)
Number of subjects: 40
Study: 9950667

Group type: EXPERIMENTAL
Intervention: Vasoflux
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hirudin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dermatan sulfate
Number of subjects: 0
Study: 7488768

Group type: EXPERIMENTAL
Intervention: Pulsatile flow (PULS-group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonpulsatile flow (CON-group)
Number of subjects: 20
Study: 2107518

Group type: EXPERIMENTAL
Intervention: Haemophilus b conjugate vaccine (meningococcal protein conjugate), PedvaxHIB (PRP‐OMPC)
Number of subjects: 0
Study: 373391

Group type: EXPERIMENTAL
Intervention: Single daily dosage of clomipramine (150 mg at night for 10 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Divided daily dosage of clomipramine (150 mg three times daily for 10 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Single daily dosage of clomipramine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Divided daily dosage of clomipramine
Number of subjects: 16
Study: 30832230

Group type: EXPERIMENTAL
Intervention: 30 g of Glutamine (Gln) for 14 days
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Glutamine (Gln) in Wistar rats on a high-fat diet (HFD)
Number of subjects: 39
Study: 30899946

Group type: EXPERIMENTAL
Intervention: SRP followed by topical use of rhubarb extract
Number of subjects: 50

Group type: COMPARATOR
Intervention: Scaling and root planning (SRP)
Number of subjects: 50
Study: 26859388

Group type: EXPERIMENTAL
Intervention: DIALOG+ intervention
Number of subjects: 0
Study: 24965335

Group type: EXPERIMENTAL
Intervention: Multiple daily insulin injections (MDI)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 609
Study: 22007679

Group type: EXPERIMENTAL
Intervention: Dual-Curing Technique (DC): Excite DSC and RelyX ARC, light-cured for 60 s
Number of subjects: 34

Group type: COMPARATOR
Intervention: Light-Curing Self-Adhering Technique (LCSA): Vertise Flow, light-cured for 60 s
Number of subjects: 34
Study: 20354445

Group type: EXPERIMENTAL
Intervention: Exercise training (EX)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 21
Study: 17623113

Group type: COMPARATOR
Intervention: Open flap debridement (OFD) alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Open flap debridement with enamel matrix derivatives (EMD)
Number of subjects: 10
Study: 16275936

Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) with autologous stem-cell transplantation (melphalan 200 mg/m2 IV or melphalan 140 mg/m2 IV plus busulfan 16 mg/kg orally)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Conventional chemotherapy (CCT; monthly courses of vincristine, melphalan, cyclophosphamide, and prednisone)
Number of subjects: 190
Study: 12561063

Group type: EXPERIMENTAL
Intervention: Intradermal injection of Tc‐99m tin colloid (0.4‐5 microm)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Subdermal injection of radiocolloids
Number of subjects: 116
Study: 10418541

Group type: EXPERIMENTAL
Intervention: Twenty‐minute educational videotape on advantages and disadvantages of prostate‐specific antigen (PSA) screening for prostate cancer
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study: 7538712

Group type: EXPERIMENTAL
Intervention: TUIP (transurethral incision of the prostate)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TURP (transurethral resection of the prostate)
Number of subjects: 120
Study: 2268864

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 to 40 mg daily for six months)
Number of subjects: 15
Study: 6104614

Group type: EXPERIMENTAL
Intervention: Nadolol (once daily for 12 weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Propranolol (four times per day for 12 weeks)
Number of subjects: 75
Study: 31734589

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) at a dose of 20Gy in 1 fraction to each metastasis
Number of subjects: 15
Study: 31229502

Group type: EXPERIMENTAL
Intervention: Virtual Learning Environment (VLE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Didactic teaching
Number of subjects: 40
Study: 30192018

Group type: EXPERIMENTAL
Intervention: Ecopipam (50 mg/day for weight <34 kg, 100 mg/day for weight >34 kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 27434094

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone alone (90 mg once daily)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Estradiol addition (2 mg twice daily)
Number of subjects: 220
Study: 25112096

Group type: EXPERIMENTAL
Intervention: Electric-thermal Bian-stone therapy (group A)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Moxibustion box therapy (group B)
Number of subjects: 41
Study: 22804796

Group type: EXPERIMENTAL
Intervention: 12-week exercise programme including pelvic floor muscle training (PFMT), conducted between 20 and 36 weeks of gestation, with one weekly group session led by physiotherapists and home exercises encouraged at least twice a week.
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: 12-week exercise programme including pelvic floor muscle training (PFMT).
Number of subjects: 855

Group type: COMPARATOR
Intervention: Standard antenatal care (control group).
Number of subjects: 855
Study: 19464164

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) in triple-negative tumours
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) in HER2-positive tumours
Number of subjects: 327
Study: 17594986

Group type: EXPERIMENTAL
Intervention: I'm-Yunity (Coriolus versicolor) 1200 mg, three times daily for 14 days
Number of subjects: 12
Study: 15446758

Group type: COMPARATOR
Intervention: NK-1 receptor antagonists (specific drug not mentioned), administered before chemotherapy and continued twice daily for five days.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard therapy with granisetron and dexamethasone.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NK-1 receptor antagonists (specific drug not mentioned), cost of Can$6.60 per dose.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NK-1 receptor antagonists (specific drug not mentioned), total cost for five days of therapy.
Number of subjects: 0
Study: 11174482

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography
Number of subjects: 1926
Study: 9628295

Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise (1 hour, 4 times per week, for 2 months at 75% of physical working capacity)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (10 boys who did not participate in any specific program)
Number of subjects: 18
Study: 7851238

Group type: EXPERIMENTAL
Intervention: Culturally specific, intensive diabetes education program (2-hour nutrition education session)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (no education session)
Number of subjects: 152
Study: 3290585

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 62
Study: 29273485

Group type: EXPERIMENTAL
Intervention: TransCon GH (0.04, 0.08, 0.16, or 0.24mg GH/kg/wk)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Omnitrope (0.08 or 0.16mg GH/kg/wk divided into 7 equal daily doses)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 27901255

Group type: EXPERIMENTAL
Intervention: Nutritional guidance
Number of subjects: 53
Study: 25211291

Group type: EXPERIMENTAL
Intervention: Individualized manual physiotherapy plus individualized exercises
Number of subjects: 90

Group type: COMPARATOR
Intervention: Individualized exercises only (Control)
Number of subjects: 90
Study: 23017200

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 1497

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1497
Study: 20668673

Group type: EXPERIMENTAL
Intervention: Indapamide, with or without perindopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18827177

Group type: EXPERIMENTAL
Intervention: 10 microg/kg bevacizumab (Avastin) administered every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15940776

Group type: EXPERIMENTAL
Intervention: ATP 90 mg once daily
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 12810413

Group type: EXPERIMENTAL
Intervention: Carrageenan (experimental phase)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (usual food intake)
Number of subjects: 20
Study: 10319666

Group type: EXPERIMENTAL
Intervention: Outdoor walking exercise program (40-60% target heart-rate, 50-60 min, 3 times per week for 8 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Outdoor walking exercise program
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study: 8752790

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 520

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Transient ischemic episodes response (100% responders)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Transient ischemic episodes response (non-100% responders)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Two or more ischemic episodes
Number of subjects: 520

Group type: COMPARATOR
Intervention: More than six episodes
Number of subjects: 520
Study: 8317411

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg (three premeal doses)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg (single morning dose)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3594278

Group type: EXPERIMENTAL
Intervention: Initial prevention program participation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reteaching of the prevention program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Previous control group participation
Number of subjects: 30
Study: 29526341

Group type: EXPERIMENTAL
Intervention: Therabite® jaw motion rehabilitation system
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wooden spatulas
Number of subjects: 71
Study: 28806907

Group type: EXPERIMENTAL
Intervention: Acupuncture (6 sessions per week for 4 weeks, total of 24 sessions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Estazolam (1-2 mg/day taken 30 minutes before sleep for 4 weeks)
Number of subjects: 40
Study: 26399940

Group type: EXPERIMENTAL
Intervention: 70% of maximum voluntary contraction (MVC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50% of maximum voluntary contraction (MVC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30% of maximum voluntary contraction (MVC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control measurement of maximum 3s position in the joint at 90°
Number of subjects: 12
Study: 23557728

Group type: EXPERIMENTAL
Intervention: McConnell taping
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spider(®) taping
Number of subjects: 20
Study: 21672316

Group type: EXPERIMENTAL
Intervention: 500 ml 6% hydroxyethyl starch 130/0.4 (HES)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 500 ml 4% succinylated gelatine (GEL)
Number of subjects: 50
Study: 18384489

Group type: EXPERIMENTAL
Intervention: Stability training of the lumbo‐pelvo‐hip complex (LPHC) for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group remained unaffected
Number of subjects: 30
Study: 16513858

Group type: COMPARATOR
Intervention: Immediate-release methylphenidate (40 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Osmotic-release methylphenidate (90 mg)
Number of subjects: 12
Study: 12753943

Group type: EXPERIMENTAL
Intervention: CEE+MPA (0.625 mg conjugated equine estrogens combined with 2.5 mg medroxyprogesterone acetate)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CEE+MPA
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 105
Study: 10946805

Group type: EXPERIMENTAL
Intervention: Amino acid-supplemented very-low-protein diet (VLPD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dialysis
Number of subjects: 0
Study: 8572841

Group type: EXPERIMENTAL
Intervention: NCEP Step I diet
Number of subjects: 89

Group type: COMPARATOR
Intervention: NCEP Step I diet with quick-service meals (NCEP-QS)
Number of subjects: 89
Study: 1741552

Group type: EXPERIMENTAL
Intervention: Human surfactant containing SP‐A
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 61
Study: 6963097

Group type: EXPERIMENTAL
Intervention: Activated charcoal administration during maintenance therapy with digoxin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activated charcoal administration during maintenance therapy with digitoxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fibre administration
Number of subjects: 0
Study: 30507562

Group type: EXPERIMENTAL
Intervention: 10‐min manual protocol of plantar stimulation on the right foot (Experimental Group, EG)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 98
Study: 28753067

Group type: EXPERIMENTAL
Intervention: CNTO 6785
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 26474237

Group type: EXPERIMENTAL
Intervention: Low-dose rifaximin (400mg every 12 hours for 2 weeks)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High-dose rifaximin (600mg every 12 hours for 2 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no rifaximin treatment)
Number of subjects: 43
Study: 23282190

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation
Number of subjects: 925
Study: 20938352

Group type: EXPERIMENTAL
Intervention: Active stimulation (anodal DC of the DLPFC)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Active stimulation (cathodal DC of the DLPFC)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Active stimulation (intermittent anodal DC of the DLPFC)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Active stimulation (AC on the zygomatic process)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 82
Study: 19603229

Group type: EXPERIMENTAL
Intervention: Alginate mesh
Number of subjects: 73

Group type: COMPARATOR
Intervention: Polyvidone iodine mesh
Number of subjects: 73
Study: 17100681

Group type: EXPERIMENTAL
Intervention: ICD-recall group
Number of subjects: 55

Group type: COMPARATOR
Intervention: ICD-control group
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: NYHA II group
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Symptomatic shock experience
Number of subjects: 55
Study: 14710204

Group type: EXPERIMENTAL
Intervention: Scientific and psychosocial information pack (Group 1)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Scientific information pack only (Group 2)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standard care control (Group 3)
Number of subjects: 163
Study: 11323358

Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine with 0.0002% fentanyl
Number of subjects: 98

Group type: COMPARATOR
Intervention: 0.1% ropivacaine with 0.0002% fentanyl
Number of subjects: 98
Study: 9218083

Group type: EXPERIMENTAL
Intervention: Zamifenacin 40 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Zamifenacin 10 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7752825

Group type: EXPERIMENTAL
Intervention: 500 mcg of selenium (as sodium selenite) followed by 100 mg coenzyme Q10 (Bio‐Quinone) and 100 mcg selenium (Bio‐Selenium in the form of 1‐seleno‐methionine) for one year
Number of subjects: 61

Group type: COMPARATOR
Intervention: Matching placebo preparations
Number of subjects: 61
Study: 3054778

Group type: EXPERIMENTAL
Intervention: Ceftriaxone, 80 to 100 mg/kg/day for 4 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Penicillin G
Number of subjects: 20
Study: 31811480

Group type: EXPERIMENTAL
Intervention: Cystine/Theanine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31473324

Group type: EXPERIMENTAL
Intervention: Targeted hypothermia (33°C)
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Normothermia and early treatment of fever (≥37.8°C)
Number of subjects: 1900
Study: 28343218

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (50 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 28
Study: 26604728

Group type: EXPERIMENTAL
Intervention: Mud Bath Therapy (MBT), n=22
Number of subjects: 42

Group type: COMPARATOR
Intervention: Leisure Thermal Activity (LTA), n=19
Number of subjects: 42
Study: 23306009

Group type: EXPERIMENTAL
Intervention: Quantitative CT densitometry (qCTD)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Baseline volume (BV)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Time-to-scan (TTS)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combined model of qCTD, BV, and TTS
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: qCTD
Number of subjects: 81
Study: 21699876

Group type: EXPERIMENTAL
Intervention: High self-efficacy regarding the ability to exert control over pain
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Anticipated pain intensity
Number of subjects: 79
Study: 18788410

Group type: EXPERIMENTAL
Intervention: Erythropoietin stimulating agents (ESAs) treatment targeting higher hemoglobin levels (near normal level)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythropoietin stimulating agents (ESAs) treatment targeting lower hemoglobin levels (sub-normal level)
Number of subjects: 0
Study: 16648977

Group type: EXPERIMENTAL
Intervention: Controlled mild hypothermia (32-34 degrees C for 12-24 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (not specified)
Number of subjects: 0
Study: 12859446

Group type: EXPERIMENTAL
Intervention: Allergen (A)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Experimental diluent (D)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Allergen (A) and Experimental diluent (D)
Number of subjects: 10
Study: 10731496

Group type: EXPERIMENTAL
Intervention: Soy sterol esters
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Beta-sitostanol ester
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 7
Study: 9186459

Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms intravenous)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1586104

Group type: EXPERIMENTAL
Intervention: Zidovudine, 1200 mg/d
Number of subjects: 711

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 711
Study: 3518121

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multimodality therapy
Number of subjects: 0
Study: 31900959

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 29738282

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg/kg BM
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10